NEW YORK (GenomeWeb) – The US Food and Drug Administration has proposed new legislative language for the Diagnostic Accuracy and Innovation Act (DAIA), departing significantly from the regulatory framework that House Representatives Larry Bucshon (R-IN) and Diana DeGette (D-CO) had drafted with extensive input from stakeholders.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.